Lv1
56 积分 2026-05-11 加入
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
29天前
已完结
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
29天前
已完结
On KEYNOTE-564, evaluating pembrolizumab vs placebo as postnephrectomy adjuvant therapy for clear cell renal cell carcinoma
29天前
已完结
Study on adjuvant therapy of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study of pembrolizumab
29天前
已完结
AUO
29天前
已完结
Consultant Oral Session Abstracts
29天前
已完结
Nivolumab (NIVO) vs ipilimumab (IPI) en traitement adjuvant du mélanome de stade III/IV opéré : résultats de survie sans récidive (SSR) et de survie globale (SG) à 4 ans de l’essai CheckMate 238
29天前
已完结
2612P Exploring the influence of adjuvant immune checkpoint inhibition on health-related quality of life in renal cell carcinoma: A qualitative sub study within the RAMPART trial
29天前
已关闭
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
29天前
已完结
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer
29天前
已关闭
皖公网安备34019202002308
